Effect of glycation on alpha-crystallin structure and chaperone-like function.
The chaperone-like activity of alpha-crystallin is considered to play an important role in the maintenance of the transparency of the eye lens. However, in the case of aging and in diabetes, the chaperone function of alpha-crystallin is compromized, resulting in cataract formation. Several post-translational modifications, including non-enzymatic glycation, have been shown to affect the chaperone function of alpha-crystallin in aging and in diabetes. A variety of agents have been identified as the predominant sources for the formation of AGEs (advanced glycation end-products) in various tissues, including the lens. Nevertheless, glycation of alpha-crystallin with various sugars has resulted in divergent results. In the present in vitro study, we have investigated the effect of glucose, fructose, G6P (glucose 6-phosphate) and MGO (methylglyoxal), which represent the major classes of glycating agents, on the structure and chaperone function of alpha-crystallin. Modification of alpha-crystallin with all four agents resulted in the formation of glycated protein, increased AGE fluorescence, protein cross-linking and HMM (high-molecular-mass) aggregation. Interestingly, these glycation-related profiles were found to vary with different glycating agents. For instance, CML [N(epsilon)-(carboxymethyl)lysine] was the predominant AGE formed upon glycation of alpha-crystallin with these agents. Although fructose and MGO caused significant conformational changes, there were no significant structural perturbations with glucose and G6P. With the exception of MGO modification, glycation with other sugars resulted in decreased chaperone activity in aggregation assays. However, modification with all four sugars led to the loss of chaperone activity as assessed using an enzyme inactivation assay. Glycation-induced loss of alpha-crystallin chaperone activity was associated with decreased hydrophobicity. Furthermore, alpha-crystallin isolated from glycated TSP (total lens soluble protein) had also increased AGE fluorescence, CML formation and diminished chaperone activity. These results indicate the susceptibility of alpha-crystallin to non-enzymatic glycation by various sugars and their derivatives, whose levels are elevated in diabetes. We also describe the effects of glycation on the structure and chaperone-like activity of alpha-crystallin.
Kumar
P Anil
PA
Biochemistry Division, National Institute of Nutrition, Hyderabad 500 007, India.
Kumar
M Satish
MS
Reddy
G Bhanuprakash
GB
D000818:Animals; D017127:Glycation End Products, Advanced / Q000737:chemistry / Q000378:metabolism; D006031:Glycosylation; D006041:Goats; D018832:Molecular Chaperones / Q000737:chemistry* / Q000378:metabolism / Q000502:physiology*; D017433:Protein Structure, Secondary / Q000502:physiology; D017434:Protein Structure, Tertiary / Q000502:physiology; D038201:alpha-Crystallins / Q000737:chemistry* / Q000378:metabolism / Q000502:physiology*
D017127:Glycation End Products, Advanced; D018832:Molecular Chaperones; D038201:alpha-Crystallins
Biochem J. 2002 Jun 15;364(Pt 3):711-7
12049635
Mol Cell Biochem. 2002 Jan;229(1-2):113-8
11936835
Eye (Lond). 2003 Jul;17(5):637-45
12855974
Biochemistry. 2003 Sep 16;42(36):10746-55
12962499
Biochem J. 2004 Apr 15;379(Pt 2):273-82
14711370
Arch Ophthalmol. 2004 Apr;122(4):525-30
15078670
Prog Biophys Mol Biol. 2004 Nov;86(3):407-85
15302206
Clin Chem. 1986 Oct;32(10 Suppl):B37-41
3530538
Biochem J. 1987 Sep 15;246(3):761-9
3689329
Prog Clin Biol Res. 1989;304:123-39
2780679
Exp Eye Res. 1991 Apr;52(4):439-44
2037022
Diabetes. 1991 Aug;40(8):1010-5
1907246
Mol Biol Rep. 1991 May;15(2):57-64
1749374
Exp Eye Res. 1992 Mar;54(3):337-45
1521566
FEBS Lett. 1992 Dec 7;314(1):1-4
1451795
J Biol Chem. 1993 Sep 5;268(25):18844-9
8395520
Mol Aspects Med. 1993;14(4):287-371
8277832
J Biol Chem. 1994 Nov 4;269(44):27264-8
7961635
Biochem Biophys Res Commun. 1995 Mar 17;208(2):675-9
7695622
Biochem Biophys Res Commun. 1995 Jul 6;212(1):184-9
7612005
FEBS Lett. 1995 Aug 7;369(2-3):321-5
7649280
Biochemistry. 1995 Aug 29;34(34):10872-8
7662668
Biochemistry. 1996 Jun 18;35(24):8075-83
8672512
Ophthalmic Res. 1996;28 Suppl 1:32-8
8727961
Drugs Aging. 1996 Aug;9(2):69-77
8820792
J Biol Chem. 1997 Feb 28;272(9):5430-7
9038143
Nephrol Dial Transplant. 1996;11 Suppl 5:20-6
9044302
Ophthalmic Res. 1997;29(6):421-8
9380344
Biochim Biophys Acta. 1997 Dec 5;1343(2):299-315
9434120
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):4882-7
9560197
Prog Retin Eye Res. 1999 Jul;18(4):463-509
10217480
Curr Eye Res. 1999 Apr;18(4):270-6
10372986
Arch Biochem Biophys. 1999 Aug 1;368(1):98-104
10415116
Diabetes Res Clin Pract. 2005 Jan;67(1):3-21
15620429
J Ethnopharmacol. 2005 Feb 28;97(2):397-403
15707781
Mol Vis. 2005;11:561-8
16088325
Mol Vis. 2006;12:205-14
16604053
Ophthalmol Clin North Am. 2006 Dec;19(4):415-25
17067897
IUBMB Life. 2006 Nov;58(11):632-41
17085382
J Biol Chem. 2000 Feb 18;275(7):4565-70
10671481
Biochem Biophys Res Commun. 2000 Jun 24;273(1):197-202
10873586
Ophthalmic Epidemiol. 2000 Jun;7(2):103-14
10934461
Cell Mol Life Sci. 2000 Jun;57(6):899-913
10950306
Biochem Biophys Res Commun. 2001 Apr 6;282(3):712-6
11401520
Exp Eye Res. 2003 Feb;76(2):145-53
12565801